Fractyl Health (NASDAQ:GUTS – Get Free Report) had its target price cut by stock analysts at Morgan Stanley to $4.00 in a report issued on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective indicates a potential upside of 189.86% from the company’s previous close.
Several other research firms have also recently issued reports on GUTS. Wall Street Zen cut Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings cut Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Finally, Craig Hallum set a $5.00 target price on Fractyl Health in a research report on Monday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $50.25.
View Our Latest Report on Fractyl Health
Fractyl Health Price Performance
Shares of GUTS stock traded down $0.17 during trading hours on Monday, hitting $1.38. 1,128,828 shares of the company’s stock were exchanged, compared to its average volume of 330,581. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41. The firm has a market cap of $18.30 million, a P/E ratio of -0.13 and a beta of 2.42. The firm has a 50 day moving average of $6.89 and a two-hundred day moving average of $8.06. Fractyl Health has a fifty-two week low of $1.37 and a fifty-two week high of $29.34.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.18. Sell-side analysts forecast that Fractyl Health will post -6.32 EPS for the current year.
Institutional Trading of Fractyl Health
Hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC purchased a new position in shares of Fractyl Health during the 2nd quarter worth $8,968,058. Bank of America Corp DE acquired a new position in shares of Fractyl Health in the 2nd quarter worth approximately $4,791,000. General Catalyst Group Management LLC acquired a new position in Fractyl Health during the second quarter worth $3,880,000. Pale Fire Capital SE boosted its holdings in Fractyl Health by 84.5% during the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after acquiring an additional 2,711,103 shares during the period. Finally, BlackRock Inc. purchased a new position in shares of Fractyl Health in the second quarter valued at approximately $1,431,000.
About Fractyl Health
Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.
Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.
Read More
- Five stocks we like better than Fractyl Health
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
